CNST Constellation Pharmaceuticals Inc.

9.77
+0.75  (+8%)
Previous Close 9.02
Open 9
Price To Book 2.92
Market Cap 252136627
Shares 25,807,229
Volume 204,036
Short Ratio
Av. Daily Volume 95,747

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim data due at ASCO on June 3, 2019, 8am CT and at EHA on June 15, 2019, 12:15 PM CEST.
CPI-0610 and ruxolitinib
Myelofibrosis
Phase 2 trial initiated.
CPI-1205 ORIOn-E
Solid tumors
Phase 2 interim data due 2H 2019.
CPI-1205 - ProSTAR
Castration-resistant prostate cancer

Latest News

  1. Constellation Pharmaceuticals Presents Poster on Studies of CPI-0209 in Bladder Cancer at AACR Meeting
  2. Constellation Pharmaceuticals Provides Interim Update of Data for CPI-0610 in ASCO and EHA Abstracts
  3. Constellation Pharmaceuticals Announces First-Quarter 2019 Financial Results
  4. Constellation Pharmaceuticals to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day
  5. Jim Cramer: What Dirty Lemon Tells Us About Market Tops and Millennials
  6. Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2018 Financial Results
  7. Constellation Pharmaceuticals to Present at Upcoming Investor Conference
  8. Constellation Pharmaceuticals Appoints Jessica Christo as Chief Product Development Officer
  9. What's in Store for Universal Health (UHS) Q4 Earnings?
  10. Constellation Pharmaceuticals to Present at Upcoming Investor Conferences
  11. Constellation Pharmaceuticals Announces Appointment to Board of Directors
  12. Molina Healthcare (MOH) Q4 Earnings & Revenues Top Estimates
  13. Ensign Group's (ENSG) Q4 Earnings Top Estimates, Surge Y/Y
  14. MEDNAX (MD) Q4 Earnings Surpass Estimates, Increase Y/Y
  15. Can Higher Revenues Buoy T-Mobile's (TMUS) Q4 Earnings?
  16. Will Revenue Growth Support GoPro's (GPRO) Q4 Earnings?
  17. Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead Programs
  18. Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
  19. The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings
  20. Constellation Pharmaceuticals Initiates Phase 2 Portion of ProSTAR Clinical Trial in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)